198 related articles for article (PubMed ID: 37731835)
21. Identification of new [1,2,4]triazolo[4,3-a]quinoxalines as potent VEGFR-2 tyrosine kinase inhibitors: Design, synthesis, anticancer evaluation, and in silico studies.
Alsaif NA; Taghour MS; Alanazi MM; Obaidullah AJ; Alanazi WA; Alasmari A; Albassam H; Dahab MA; Mahdy HA
Bioorg Med Chem; 2021 Sep; 46():116384. PubMed ID: 34479065
[TBL] [Abstract][Full Text] [Related]
22. Design, synthesis, molecular docking and anticancer evaluations of 5-benzylidenethiazolidine-2,4-dione derivatives targeting VEGFR-2 enzyme.
El-Adl K; El-Helby AA; Sakr H; Eissa IH; El-Hddad SSA; M I A Shoman F
Bioorg Chem; 2020 Sep; 102():104059. PubMed ID: 32653608
[TBL] [Abstract][Full Text] [Related]
23. New quinoxaline-based VEGFR-2 inhibitors: design, synthesis, and antiproliferative evaluation with
Alanazi MM; Elkady H; Alsaif NA; Obaidullah AJ; Alkahtani HM; Alanazi MM; Alharbi MA; Eissa IH; Dahab MA
RSC Adv; 2021 Sep; 11(48):30315-30328. PubMed ID: 35493991
[TBL] [Abstract][Full Text] [Related]
24. New quinoxaline derivatives as VEGFR-2 inhibitors with anticancer and apoptotic activity: Design, molecular modeling, and synthesis.
Alsaif NA; Dahab MA; Alanazi MM; Obaidullah AJ; Al-Mehizia AA; Alanazi MM; Aldawas S; Mahdy HA; Elkady H
Bioorg Chem; 2021 May; 110():104807. PubMed ID: 33721808
[TBL] [Abstract][Full Text] [Related]
25. 5-(4-Methoxybenzylidene)thiazolidine-2,4-dione-derived VEGFR-2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluations.
El-Adl K; Sakr H; Nasser M; Alswah M; Shoman FMA
Arch Pharm (Weinheim); 2020 Sep; 353(9):e2000079. PubMed ID: 32515896
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis, molecular docking, anticancer evaluations, and in silico pharmacokinetic studies of novel 5-[(4-chloro/2,4-dichloro)benzylidene]thiazolidine-2,4-dione derivatives as VEGFR-2 inhibitors.
El-Adl K; El-Helby AA; Sakr H; Ayyad RR; Mahdy HA; Nasser M; Abulkhair HS; El-Hddad SSA
Arch Pharm (Weinheim); 2021 Feb; 354(2):e2000279. PubMed ID: 33073374
[TBL] [Abstract][Full Text] [Related]
27. New [1,2,4]triazolo[4,3-c]quinazoline derivatives as vascular endothelial growth factor receptor-2 inhibitors and apoptosis inducers: Design, synthesis, docking, and antiproliferative evaluation.
Azab AE; Alesawy MS; Eldehna WM; Elwan A; Eissa IH
Arch Pharm (Weinheim); 2022 Oct; 355(10):e2200133. PubMed ID: 35822666
[TBL] [Abstract][Full Text] [Related]
28. Discovery of new quinoxaline-2(1H)-one-based anticancer agents targeting VEGFR-2 as inhibitors: Design, synthesis, and anti-proliferative evaluation.
El-Adl K; Sakr HM; Yousef RG; Mehany ABM; Metwaly AM; Elhendawy MA; Radwan MM; ElSohly MA; Abulkhair HS; Eissa IH
Bioorg Chem; 2021 Sep; 114():105105. PubMed ID: 34175720
[TBL] [Abstract][Full Text] [Related]
29.
Elkaeed EB; Yousef RG; Elkady H; Mehany ABM; Alsfouk BA; Husein DZ; Ibrahim IM; Metwaly AM; Eissa IH
J Biomol Struct Dyn; 2023; 41(16):7986-8001. PubMed ID: 36184591
[TBL] [Abstract][Full Text] [Related]
30. Design, Synthesis, Molecular Modeling, and Anticancer Evaluation of New VEGFR-2 Inhibitors Based on the Indolin-2-One Scaffold.
Abdelgawad MA; Hayallah AM; Bukhari SNA; Musa A; Elmowafy M; Abdel-Rahman HM; Abd El-Gaber MK
Pharmaceuticals (Basel); 2022 Nov; 15(11):. PubMed ID: 36422546
[TBL] [Abstract][Full Text] [Related]
31. Discovery of new nicotinamides as apoptotic VEGFR-2 inhibitors: virtual screening, synthesis, anti-proliferative, immunomodulatory, ADMET, toxicity, and molecular dynamic simulation studies.
Yousef RG; Ibrahim A; Khalifa MM; Eldehna WM; Gobaara IMM; Mehany ABM; Elkaeed EB; Alsfouk AA; Metwaly AM; Eissa IH
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1389-1403. PubMed ID: 35577416
[TBL] [Abstract][Full Text] [Related]
32. (
Yousef RG; Elkady H; Elkaeed EB; Gobaara IMM; Al-Ghulikah HA; Husein DZ; Ibrahim IM; Metwaly AM; Eissa IH
Molecules; 2022 Nov; 27(22):. PubMed ID: 36431818
[TBL] [Abstract][Full Text] [Related]
33. Design, synthesis,
Saleh AM; Mahdy HA; El-Zahabi MA; Mehany ABM; Khalifa MM; Eissa IH
RSC Adv; 2023 Jul; 13(32):22122-22147. PubMed ID: 37492514
[TBL] [Abstract][Full Text] [Related]
34. Design, synthesis,
Aziz NAAM; George RF; El-Adl K; Mahmoud WR
RSC Adv; 2022 Apr; 12(20):12913-12931. PubMed ID: 35496328
[TBL] [Abstract][Full Text] [Related]
35. New Series of VEGFR-2 Inhibitors and Apoptosis Enhancers: Design, Synthesis and Biological Evaluation.
Abdallah AE; Mabrouk RR; Elnagar MR; Farrag AM; Kalaba MH; Sharaf MH; El-Fakharany EM; Bakhotmah DA; Elkaeed EB; Al Ward MMS
Drug Des Devel Ther; 2022; 16():587-606. PubMed ID: 35281317
[TBL] [Abstract][Full Text] [Related]
36. Design and synthesis of thiazolidine-2,4-diones hybrids with 1,2-dihydroquinolones and 2-oxindoles as potential VEGFR-2 inhibitors:
Taghour MS; Elkady H; Eldehna WM; El-Deeb NM; Kenawy AM; Elkaeed EB; Alsfouk AA; Alesawy MS; Metwaly AM; Eissa IH
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1903-1917. PubMed ID: 35801403
[TBL] [Abstract][Full Text] [Related]
37. New nicotinamide derivatives as potential anticancer agents targeting VEGFR-2: design, synthesis,
Yousef RG; Eissa IH; Elkady H; Eldehna WM; Mehany ABM; Nabeeh A; Ibrahim IM; Elwan A; El-Zahabi MA
J Biomol Struct Dyn; 2023 Dec; ():1-18. PubMed ID: 38100580
[TBL] [Abstract][Full Text] [Related]
38. Computer-assisted drug discovery (CADD) of an anti-cancer derivative of the theobromine alkaloid inhibiting VEGFR-2.
Eissa IH; Yousef RG; Asmaey MA; Elkady H; Husein DZ; Alsfouk AA; Ibrahim IM; Elkady MA; Elkaeed EB; Metwaly AM
Saudi Pharm J; 2023 Dec; 31(12):101852. PubMed ID: 38028225
[TBL] [Abstract][Full Text] [Related]
39. Design and biological evaluation of 3-substituted quinazoline-2,4(1
Hassan A; Mubarak FAF; Shehadi IA; Mosallam AM; Temairk H; Badr M; Abdelmonsef AH
J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2189578. PubMed ID: 36919632
[TBL] [Abstract][Full Text] [Related]
40. Design, synthesis and molecular docking of new [1,2,4] triazolo[4,3-a]quinoxaline derivatives as anticancer agents targeting VEGFR-2 kinase.
Alsaif NA; Elwan A; Alanazi MM; Obaidullah AJ; Alanazi WA; Alasmari AF; Albassam H; Mahdy HA; Taghour MS
Mol Divers; 2022 Aug; 26(4):1915-1932. PubMed ID: 34460053
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]